文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

为您的患者选择合适的益生菌产品:基于证据的实用指南。

Choosing an appropriate probiotic product for your patient: An evidence-based practical guide.

机构信息

Department of Internal Medicine, Infectious Disease Section, Florida Hospital Orlando, Orlando, FL, United States of America.

Department of Medicinal Chemistry, School of Pharmacy, University of Washington Medical Center, Seattle, Washington United States of America.

出版信息

PLoS One. 2018 Dec 26;13(12):e0209205. doi: 10.1371/journal.pone.0209205. eCollection 2018.


DOI:10.1371/journal.pone.0209205
PMID:30586435
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6306248/
Abstract

INTRODUCTION: Clinicians and patients face a daunting task when choosing the most appropriate probiotic for their specific needs. Available preparations encompass a diverse and continuously expanding product base, with most available products lacking evidence-based trials that support their use. Even when evidence exists, not all probiotic products are equally effective for all disease prevention or treatment indications. At this point in time, drug regulatory agencies offer limited assistance with regard to guidance and oversight in most countries, including the U.S. METHODS: We reviewed the current medical literature and sources on the internet to survey the types of available probiotic products and to determine which probiotics had evidence-based efficacy data. Standard medical databases from inception to June 2018 were searched and discussions with experts in the field were conducted. We graded the strength of the evidence for probiotics having multiple, randomized controlled trials and developed a guide for the practical selection of current probiotic products for specific uses. RESULTS: We found the efficacy of probiotic products is both strain-specific and disease-specific. Important factors involved in choosing the appropriate probiotic include matching the strain(s) with the targeted disease or condition, type of formulation, dose used and the source (manufacturing quality control and shelf-life). While we found many probiotic products lacked confirmatory trials, we found sufficient evidence for 22 different types of probiotics from 249 trials to be included. For example, several types of probiotics had strong evidence for the prevention of antibiotic-associated diarrhea [Saccharomyces boulardii I-745, a three-strain mixture (Lactobacillus acidophilus CL1285, L. casei Lbc80r, L. rhamnosus CLR2) and L. casei DN114001]. Strong evidence was also found for four types of probiotics for the prevention of a variety of other diseases/conditions (enteral-feed associated diarrhea, travellers' diarrhea, necrotizing enterocolits and side-effects associated with H. pylori treatments. The evidence was most robust for the treatment of pediatric acute diarrhea based on 59 trials (7 types of probiotics have strong efficacy), while an eight-strain multi-strain mixture showed strong efficacy for inflammatory bowel disease and two types of probiotics had strong efficacy for irritable bowel disease. Of the 22 types of probiotics reviewed, 15 (68%) had strong-moderate evidence for efficacy for at least one type of disease. CONCLUSION: The choice of an appropriate probiotic is multi-factored, based on the mode and type of disease indication and the specific efficacy of probiotic strain(s), as well as product quality and formulation. TRIAL REGISTRATION: This review was registered with PROSPERO: CRD42018103979.

摘要

简介:当临床医生和患者需要根据特定需求选择最合适的益生菌时,他们面临着艰巨的任务。现有的制剂涵盖了多样化且不断扩大的产品基础,大多数可用产品缺乏支持其使用的基于证据的试验。即使存在证据,也不是所有的益生菌产品对所有疾病预防或治疗适应症都同样有效。在这个时候,药物监管机构在大多数国家(包括美国)提供的指导和监督方面提供的帮助有限。

方法:我们回顾了当前的医学文献和互联网上的资料,以调查可用益生菌产品的类型,并确定哪些益生菌具有基于证据的疗效数据。从最初到 2018 年 6 月,我们搜索了标准医学数据库,并与该领域的专家进行了讨论。我们对具有多项随机对照试验的益生菌的证据强度进行了分级,并为特定用途的当前益生菌产品的实用选择制定了指南。

结果:我们发现益生菌产品的疗效具有菌株特异性和疾病特异性。选择合适的益生菌的重要因素包括将菌株与目标疾病或病症相匹配、制剂类型、使用剂量以及来源(制造质量控制和保质期)。虽然我们发现许多益生菌产品缺乏确证试验,但我们发现有足够的证据支持从 249 项试验中纳入 22 种不同类型的益生菌。例如,几种类型的益生菌对预防抗生素相关性腹泻(Saccharomyces boulardii I-745,三菌株混合物(Lactobacillus acidophilus CL1285、L. casei Lbc80r、L. rhamnosus CLR2)和 L. casei DN114001)具有强有力的证据。对于预防各种其他疾病/病症(肠内喂养相关腹泻、旅行者腹泻、坏死性小肠结肠炎和与 H. pylori 治疗相关的副作用)的四种益生菌也有强有力的证据。基于 59 项试验(7 种益生菌具有强大的疗效),对于儿科急性腹泻的治疗证据最为可靠,而一种八菌株多菌株混合物对炎症性肠病具有强大的疗效,两种益生菌对肠易激综合征具有强大的疗效。在审查的 22 种益生菌中,有 15 种(68%)对至少一种疾病的疗效有强有力的证据。

结论:选择合适的益生菌是多方面的,基于疾病的模式和类型以及益生菌菌株的具体疗效,以及产品质量和制剂。

试验注册:本综述已在 PROSPERO 注册:CRD42018103979。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/754c/6306248/b08ada823bd1/pone.0209205.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/754c/6306248/6179c6ac94d8/pone.0209205.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/754c/6306248/b08ada823bd1/pone.0209205.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/754c/6306248/6179c6ac94d8/pone.0209205.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/754c/6306248/b08ada823bd1/pone.0209205.g002.jpg

相似文献

[1]
Choosing an appropriate probiotic product for your patient: An evidence-based practical guide.

PLoS One. 2018-12-26

[2]
Strain-Specificity and Disease-Specificity of Probiotic Efficacy: A Systematic Review and Meta-Analysis.

Front Med (Lausanne). 2018-5-7

[3]
Probiotics for the prevention of pediatric antibiotic-associated diarrhea.

Cochrane Database Syst Rev. 2015-12-22

[4]
Probiotics for the prevention of pediatric antibiotic-associated diarrhea.

Cochrane Database Syst Rev. 2011-11-9

[5]
Probiotics for the Prevention of Pediatric Antibiotic-Associated Diarrhea.

Explore (NY). 2016

[6]
The Acid-Dependent and Independent Effects of Lactobacillus acidophilus CL1285, Lacticaseibacillus casei LBC80R, and Lacticaseibacillus rhamnosus CLR2 on Clostridioides difficile R20291.

Probiotics Antimicrob Proteins. 2021-8

[7]
Primary prevention of Clostridium difficile infections with a specific probiotic combining Lactobacillus acidophilus, L. casei, and L. rhamnosus strains: assessing the evidence.

J Hosp Infect. 2018-4-24

[8]
Efficacy of Single-Strain Probiotics Versus Multi-Strain Mixtures: Systematic Review of Strain and Disease Specificity.

Dig Dis Sci. 2021-3

[9]
Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R, and Lactobacillus rhamnosus CLR2 (Bio-K+): Characterization, Manufacture, Mechanisms of Action, and Quality Control of a Specific Probiotic Combination for Primary Prevention of Clostridium difficile Infection.

Clin Infect Dis. 2015-5-15

[10]
A meta-analysis of probiotic efficacy for gastrointestinal diseases.

PLoS One. 2012-4-18

引用本文的文献

[1]
Antimicrobial Peptides as Next-Generation Disinfectants: Tackling Biocide and Antimicrobial Resistance in Hospital Hygiene - A Narrative Review.

Probiotics Antimicrob Proteins. 2025-8-20

[2]
Probiotics in inflammatory bowel diseases: emphasis on mechanisms and clinical application.

Front Med (Lausanne). 2025-8-1

[3]
Effect of a Probiotic Combination on Clinical and Microbiological Oral Parameters in Head and Neck Cancer Patients: A Randomised Clinical Trial.

Cancers (Basel). 2025-7-25

[4]
Effect of subsp. YLGB-1496 on common diseases in pediatrics: a randomized, blinded, placebo-controlled trial.

Front Nutr. 2025-7-1

[5]
Probiotics and Cancer: Mechanistic Insights and Organ-Specific Impact.

Biomolecules. 2025-6-16

[6]
Probiotics and Oral Complications of Antineoplastic Therapy in Head and Neck Cancer: A Systematic Review and Meta-Analysis.

Dent J (Basel). 2025-6-6

[7]
Folate Production by IDCC 2201 and Its Impact on Human Gut Microbiota.

J Microbiol Biotechnol. 2025-5-28

[8]
Clinical practice guidelines for acute infectious diarrhea in children in China (2024).

World J Pediatr. 2025-5-29

[9]
On the Knowledge and Prescription of Probiotics by Pediatric Providers: A Cross-Sectional Study.

Nutrients. 2025-3-10

[10]
Antibiotic Resistance Gene Expression in Veterinary Probiotics: Two Sides of the Coin.

Vet Sci. 2025-3-2

本文引用的文献

[1]
Epidemiology and healthcare factors associated with neonatal enterococcal infections.

Arch Dis Child Fetal Neonatal Ed. 2018-11-13

[2]
Harms Reporting in Randomized Controlled Trials of Interventions Aimed at Modifying Microbiota: A Systematic Review.

Ann Intern Med. 2018-7-17

[3]
Strain-Specificity and Disease-Specificity of Probiotic Efficacy: A Systematic Review and Meta-Analysis.

Front Med (Lausanne). 2018-5-7

[4]
Primary prevention of Clostridium difficile infections with a specific probiotic combining Lactobacillus acidophilus, L. casei, and L. rhamnosus strains: assessing the evidence.

J Hosp Infect. 2018-4-24

[5]
Effectiveness of Probiotic for Primary Prevention of Clostridium difficile Infection: A Single-Center Before-and-After Quality Improvement Intervention at a Tertiary-Care Medical Center.

Infect Control Hosp Epidemiol. 2018-4-26

[6]
Treatment efficacy of probiotics on atopic dermatitis, zooming in on infants: a systematic review and meta-analysis.

Int J Dermatol. 2018-2-8

[7]
Benefits of probiotics in preterm neonates in low-income and medium-income countries: a systematic review of randomised controlled trials.

BMJ Open. 2017-12-7

[8]
2017 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea.

Clin Infect Dis. 2017-11-29

[9]
Commercial Probiotic Products: A Call for Improved Quality Control. A Position Paper by the ESPGHAN Working Group for Probiotics and Prebiotics.

J Pediatr Gastroenterol Nutr. 2017-7

[10]
Probiotic guidelines and physician practice: a cross-sectional survey and overview of the literature.

Benef Microbes. 2017-8-24

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索